Title of Invention

PROCESS FOR THE PREPARATION OF GALANTHAMINE HYDROBROMIDE

Abstract The invention discloses a process for the purification of galanthamine (I) said process consisting of the following steps: a) addition of hydrobromic acid to a mixture of alkaloids containing galanthamine obtained from a plant of the Amaryllidaceae family, said mixture being dissolved in a solvent selected from methanol, ethanol, propanol or isopropanol; b) recovery of the precipitate; c) dissolution of the precipitate in a basic aqueous solution; d) extraction with a solvent of general formula (II) in which R1 is hydrogen or methyl and R2 is selected from n-butyl, isobutyl, sec- butyl and t-butyl; e) concentration of the organic phase; f) recovery of the precipitated galanthamine (I) by known method.
Full Text field of the invention
The invention relates to the purification of tetracylic alkaloids, in
particular to the purification of galanmamine.
Background of the invention
Galanthamine, ((-)-[4aS-C4aα,6β,8aR)]-4a,5,9,10,ll,12 - hexahydro - 3
- methoxy - 11 - methyl - 6H - benzofuro[ 3a, 3, 2, - e f ] [2] benzazepine - 6 -
ol) (I),

is a tetracylic alkaloid which reversibly inhibits cholmesterase. Its effects are
similar to those of physostigmine and neostigmine, but its inhibitory effect is
lower. However, this drawback is counterbalanced by a broader therapeutical
spectrum and lower toxicity. Galanthamine is used for the treatment of
narrow-angle glaucoma, intoxications, nicotine and alcohol dependency and
different pathologies of the nervous system, such as the Alzheimer's
syndrome. For clinical purposes, it is administered in the form of
hydrobromide, whose preparation was first described in the fifties (N.F.
Proskuroina et aL, Zhur.Obshchei Khim. 22, 1899 (1952)).
Galanthamine can be prepared by total synthesis, but due to the
presence of three chiral centres, the metodologies are particularly complicated.
More commonly, galanthamine is isolated from plants of the Amaryttidaceae
family, for example plants of the genus Galanthus, Crinum, Leucojum and

Narcissus which also contain several galanthamine-related compounds. In
these plants galanthamine can be present in traces or in the maxinwrn amount
of 0.3%. However, many of these plants are protected species and therefore
the recovery of galanthamine on an industrial scale requires the use of
biomasses obtained from cultivations.
The presence of a relevant number of galanthamine structurally-related
compounds makes it troublesome and often expensive to recover galanthamine
in a purity suitable for the pharmaceutical use, in particular for the preparation
of galanthamine hydrobromide.
The preparation of mixtures of galanthamine and related compounds
from plant materials is generally carried out using conventional methods for
the extraction of alkaloids, which comprise wetting the plant material with
alkali solutions suitable for hydrolysing the alkaloid salts contained in the
biomass to free bases and extracting with solvents wherein the alkaloid bases
are soluble.
In the particular case of galanthamine-containing plants, the alkali
solutions are solutions of inorganic bases such as sodium, calcium, potassium
hydroxide or carbonate or solutions of ammonium hydroxide. Water-miscible
solvents such as methanol, ethanol and acetone, or water-immiscible solvents,
such as aliphatic and aromatic hydrocarbons or esters, for example ethyl
acetate, can be used as extraction solvents. Extractions can be carried out at
temperatures ranging from 20°C to the boiling temperature of the solvent.
Preferably, concentrated aqueous solutions of sodium carbonate can be used
for the hydrolysis of the alkaloid bases; for the extractions, toluene at
temperatures ranging from 20 to 70°C can be used. With respect to the other
solvents mentioned above, toluene has the advantage of satisfactorily
exhausting the alkaloids while avoiding the extraction of polar constituents
which would make the subsequent purification steps troublesome.

The alkaloids contained in the toluene extracts can bs separated; &m
4he.jioiL-alkaloid components. by. extraction with. an^!aci4ic\f^|pn^:s^ni^^'
for;.'example a 2% sulfuric acid, solution, followed %^^ajiiii^fen};;^ith
SQdiiimor potassium hydroxide, or sodium or potassium .:cwfc:onate;,anjl;smgie.
re-extraction with toluene, -whereby the alkaloid components are obtained as a
mixture.
These procedures allow to obtain from AmarylEddceae- complex-
mixtures of alkaloids haying a galanthamine content ranging from 30 to 40%.
There is still therefore the need for a purification process which provides
galantha:mine suitable for pharmaceutical use.
GB 938 767 discloses a method for extracting galanthamine from Amaryllidaceae
and teaches that this alkaloid can be used far preparing the corresponding hydrobromide,
which represents the final result.
GB 938 767 discloses a process in which crude galanthamine is dissolved in
acetone and added with aluminium oxide to remove impurities; after appropriate stirring
the aluminium oxide is filtered off and the resulting acetone solution added with
hydrobromide acid provide pure galanthamine hydrobromide.
GB 938 767 teaches to prepare galanthamine hydrobromide as a final product, not
as an intermediate for the purification of galanthamine.
GB 942 200 - teaches to purify galanthamine first by passing a solution of crude
galanthamine through an ion exchange resin and/or an activated acidic clay and then to
prepare the hydrobromide, by treating the purified galanthamine obtained after elution of
the solvent with hydrobromic acid in an alcoholic or ketonic solution.

US 2002/028802 - teaches the purification of galanthamine through liquid-liquid
extraction, characterised in that the first extraction step is carried out at a pH of about 4.
It is generically stated that galanthamine is purified by galanthamine hydrobromide;
however, this statement refers to known methods, which comprise the extraction of
galanthamine from the plant and the treatment of the extract with alumina. Thus, US
2002/028802 also does not teach to add hydrobromic acid directly to a mixture of
alkaloids containing galanthamine, as in the present invention.
European Journal of Medicinal Chemistry, vol.27, no.7 (1992), pages 673-687 -
which envisages the use of galanthamine hydrobromide, comprises either neutralization
of galanthamine hydrobromide with ammonium hydroxide or its treatment with ammonia
followed by the purification of the resulting crude galanthamine by silica gel-flash
chromatography using acetone and acetone/methanol as eluents to afford pure
galanthamine.
US 2003/092700 - discloses galanthamine-related compounds and the preparation
thereof; the preparation of the corresponding halides is also disclosed.
CN 1 490 319 - discloses the purification of galanthamine through counter-
current extraction. This process is carried out using a solvent mixture comprising solvents
that act as the stationary phase and solvents that act as the mobile phase for the extraction
of the product. Butyl acetate is mentioned as one of the components of a mixture
comprising at least three solvents. Thus CN CN 1 490 319 teaches the use of apolar
solvent, like, butyl acetate in the purification process.
In contrast, the claimed process of the present invention, starts from a solution of
alkaloids in a solvent selected from methanol, ethanol, propanol and isopropanol; this
solution is first treated with hydrobromic acid to give a precipitate of hydrobromide salts,
which is neutralised with a basic solution, extracted and concentrated to give pure
galanthamine. In the prior art this step sequence is neither disclosed nor suggested.
None of the prior art documents suggests to purify galanthamine hydrobromide
first and then isolate pure galanthamine.

DetaDed description of the invention •
It has now been found that highly pure gala-thamine for pharmaceutical
use can be obtained precipitating galanthamine (I)

.as hydrobromide from an alkaloids mixture containing galaathamine obtained
from a plant belonging to the Amaryllidaceaa family, hydrolysing tie
hydrobromide and extracting galaatharciae ■with a suitable solvent.
In particular, the invention relates to a process comprising the following
steps:
a) addition of hydrobromic acid to a mixture of alkaloids containing
galanthamine obtained from a plant of the Amaryllidacece family;
b) recovery of the precipitate;
c) dissolution of tbe precipitate in a basic aqueous solution;
d) extraction with a solvent of general formula (U)


in which Ri is hydrogen or methyl and R2 is selected from n-butyl,
isobutyl, sec-butyl and tert-butyl;
e) concentration of the organic phase;
f) optional recovery of the precipitated galanthamine (I).
The preparation of the alkaloids mixture can be carried out according to
conventional methods, for example according to what described in the
background of the invention.
The precipitation of galanthamine hydrobromide from the alkaloids
mixture is carried out preferably with aqueous hydrobromic acid in an
alcoholic solvent, for example in methanol, ethanol, propanol or iso-propanol,
preferably ethanol. The salification is carried out keeping the temperature
from -20 to 20°C, preferably from 0 to 5°C during the addition of
hydrobromic acid, using 5 to 7 volumes of solvent compared with the weight
of the alkaloids mixture and a 5-10% excess of hydrobromic acid to the
stoichiometric amount, assuming that the alkaloids have the same molecular
weight as galanthamine (287 m.u.).
The precipitation of galanthamine hydrobromide allows to increase the
purity from 30-40% to 85-90%, with substantially quantitative recovery, since
the mother liquors contain only traces of galanthamine hydrobromide.
The alkali aqueous solutions used for dissolving the precipitate, i.e. to
hydrolyse galanthamine from the hydrobromide salt, are preferably aqueous
solutions at pH ^8, containing for example sodium carbonate, potassium
carbonate or ammonium hydroxide.
Even if the solvents of general formula (EQ used for the extraction and
precipitation of galanthamine base are not frequently used for the extraction

and especially for the crystallization of alkaloids, they give surprisingly good
results in the extraction and crystallization of galanthamine. A preferred
solvent is n-butyl acetate; after extraction the organic phase is concentrated
under vacuum until incipient crystallization.
After filtration galanthamine sufficiently pure for conversion to
hydrobromide for the pharmaceutical use is obtained in 85% yield.
The preparation of galanthamine hydrobromide from galanthamine
obtained according to the process of the present invention can be carried out
with conventional methods generally used for the salification of alkaloids.
For this purpose, galanthamine is dissolved in a suitable solvent,
preferably acetone, or an alcohol, preferably 95% ethanol, and added at 0 to
5°C with a stoichiometric amount of aqueous hydrobromic acid. According to
a particularly preferred embodiment of the invention, the hydrobromide can be
prepared without isolating galanthamine. After extraction with /j-butyl acetate
the combined organic extracts are concentrated to about 1/16 of the volume,
then the solvent and hydrobromic acid are added as described above. After
filtration and crystallization from water, galanthamine hydrobromide is
obtained with purity higher than 99%, the content of each impurity being
lower than 0.1%. The product is therefore suitable for pharmaceutical use.
The following examples illustrate the invention in greater detail.
EXAMPLES
Example 1 - Preparation of a mixtnre of alkaloids from Narcissus
Pseudonarcissus "Carlton" bulbs
Ground vegetable material (500 kg) containing 0.3% galanthamine is
added with 850 1 of 10% w/v aqueous sodium carbonate and extracted with 7 x
1000 1 toluene operating at 65-70°C.
The extracts are combined and concentrated under vacuum to a volume of
300 1. The concentrated solution is treated with 50 1 of 2% sulfuric acid and the

aqueous phase is collected The aqueous phase is adjusted to pH 9 by addition of
ammonium hydroxide and the resulting solution is extracted with 4 x 50 1 of
toluene. The combined organic phases are concentrated to dryness under vacuum.
3.5 kg of total alkaloids are obtained containing 40% galanthamine (HPLC
analysis).
Example 2 - Preparation of galanthamine by crystallization from
n-butyl acetate
Total alkaloids (3.5 kg) containing 40% galanthamine, obtained
according to example 1, are dissolved in 20 1 of 95% ethanol. The solution is
cooled to 0°C and added under stirring with 2.1 1 of 48% aqueous
hydrobromic acid, keeping the temperature during the addition between 0 and
5°C. The mixture is left under stirring at room temperature for four hours, the
product is recovered by filtration, washed with 95% ethanol and dried under
vacuum at 60°C. 2.22 kg of galanthamine hydrobromide having HPLC purity
of 88% are obtained. The filtration mother liquors, which contain traces of
galanthamine hydrobromide, are removed.
The resulting 88% galanthamine hydrobromide is suspended in 7.6 1 of
water. The suspension is cooled to 09C and diluted, keeping the temperature from
0 to 5°C, with 521 of 10% sodium carbonate. Five extractions with 51 of «-butyl
acetate are obtained, the organic phases arc pooled and washed with 2.5 1 of
salted water. The organic phases are concentrated under vacuum to a volume of
4 1 and allowed to crystallize at room temperature. The crystals are filtered and
dried under vacuum at 70°C. 1.2 kg of galanthamine are obtained with chemical-
physical and spectroscopical characteristics consistent with those reported in the
literature (P. Carroll et aL, Bull. Soc. Chim. Fr. (1990), 127,769).
Example 3 - Preparation of galanthamine by crystallization from
/-butyl acetate
Total alkaloids (3.5 kg) containing 40% galanthamine, obtained

according to example 1, are dissolved in 24 1 of isopropanol. The solution,
cooled to 0°C, is treated under stirring with 2.11 of 48% aqueous hydrobromic
acid, keeping the temperature during the addition between 0 and 5°C. The
mixture is left under stirring at room temperature for three hours, then filtered
and the solid is washed with some isopropanol and dried under vacuum at
70°C. 2.28 kg of galanthamine hydrobromide having HPLC purity of 85% are
obtained. The resulting solid is suspended in 8 1 of water, cooled to 0°C and
diluted with 5.5 1 of 10% sodium carbonate. Seven extractions with 5 1 of
/-butyl acetate are carried out.
The organic phases are pooled, washed with 3 1 of salted water and
concentrated under vacuum to 4.4 1, then left to crystallize at room
temperature. The resulting crystals are filtered and dried under vacuum at
70°C. 1.25 kg of galanthamine having the same quality as that of example 2
are obtained.
Example 4 - Preparation of galanthamine hydrobromide having a
purity not lower than 99%
Galanthamine obtained according to examples 2 and 3 (1.64 kg) is
dissolved in 11.5 1 of 95% ethanol. The solution is cooled to 0°C and treated
under stirring with 0.76 1 of 48% hydrobromic acid, keeping the temperature
at 0-5°C during the addition.
The mixture is left to stand for four hours and filtered, washing the
precipitate with 1.5 1 of 95% ethanol. The wet solid is dissolved at 50°C in
18 1 of 30% aqueous ethanol and the solution is concentrated under vacuum to
a volume of 6 1 and left to crystallize overnight. The crystallized solid is
filtered, washed with 1.9 1 of water and dried under vacuum at 50°C. 1.9 kg of
galanthamine hydrobromide having HPLC purity higher than 99% are
obtained, each impurity being lower than 0.1%.
Example 5 - Preparation of galanthamine hydrobromide having

purity not lower than 99%
Total alkaloids (3.5 kg) containing 40% galanthamine, obtained
according to example 1, are dissolved in 20 1 of 95% ethanol. The solution is
cooled to 0°C and treated under stirring with 2.1 1 of 48% aqueous
hydrobromic acid, keeping the temperature during the addition between 0 and
5°C. The mixture is left under stirring at room temperature for four hours, the
product is collected by filtration, washed with 95% ethanol and dried under
vacuum at 60°C. 2.22 kg of galanthamine hydrobromide are obtained having
HPLC purity of 88%. The mother liquors from filtration, which contain traces
of galanthamine hydrobromide, are removed.
The resulting 88% galanthamine hydrobromide is suspended in 7.6 1 of
water. The suspension is cooled to 0°C and diluted with 5.2 1 of 10% sodium
carbonate, keeping the temperature from 0 to 5°C and extracted with 5 x 51 of
/j-butyl-acetate. The organic phases are pooled, washed with 2.5 1 of salted
water, concentrated under vacuum to a volume of 1.6 1 and then added with
8.4 1 of 95% ethanol. The solution is cooled to 0°C and added under stirring
with 0.56 1 of 48% hydrobromic acid, keeping the temperature at 0-5°C.
The mixture is allowed to stand for four hours and filtered, washing the
precipitate with 1.1 1 of 95% ethanol. The wet solid is dissolved at 50°C in
13.2 1 of 30% aqueous ethanol, the solution is concentrated under vacuum to a
volume of 4.4 1 and left to crystallize overnight. The resulting crystals are
filtered, washed with 1.41 of water and dried under vacuum at 50°C. 1.4 kg of
galanthamine hydrobromide having HPLC purity higher than 99% is obtained,
each impurity being lower than 0.1%.

We claim:
1. A process for the purification of galanthamine (I)

said process consisting of the following steps:
a) addition of hydrobromic acid to a mixture of alkaloids containing
galanthamine obtained from a plant of the Amaryllidaceae family, said
mixture being dissolved in a solvent selected from methanol, ethanol,
propanol or isopropanol;
b) recovery of the precipitate;
c) dissolution of the precipitate in a basic aqueous solution;
d) extraction with a solvent of general formula (II)

in which R1 is hydrogen or methyl and R2 is selected from n-butyl,
isobutyl, sec-butyl and t-butyl;
e) concentration of the organic phase;
f) recovery of the precipitated galanthamine (I) by known method.

2. A process as claimed in claim 1 in which the solvent is ethanol.
3. A process as claimed in claim 1 or 2 in which the solvent for step a) is added
in amounts ranging from 5 to 7 volumes on the weight of the mixture of alkaloids.
4. A process as claimed in any one of claims 1 to 3 in which hydrobromic acid
is added as aqueous hydrobromic acid.
5. A process as claimed in any one of claims 1 to 4 in which the addition is

carried out at a temperature ranging from -20 to 20°C.
6. A process as claimed in claim 5 in which the temperature ranges from
0 to 5°C.
7. A process as claimed in any one of claims 4 to 6 in which hydrobromic acid
exceeds by 5-10% the calculated galanthamine content in the mixture.
8. A process as claimed in any one of claims 1 to 7 in which the aqueous basic
solution is a basic aqueous solution at pH ≥ 8 and the base is selected from sodium,
potassium, calcium hydroxide or carbonate and ammonium hydroxide.
9. A process as claimed in any one of claims 1 to 8 in which the solvent of
general formula (II) is n-butyl acetate.
10. A process as claimed in any one of the above claims optionally comprising
the conversion of galanthamine into galanthamine hydrobromide.
11. A process as claimed in claim 10 in which the conversion into galanthamine
hydrobromide is carried out without isolating galanthamine.


The invention discloses a process for the purification of galanthamine (I)

said process consisting of the following steps: a) addition of hydrobromic acid to a
mixture of alkaloids containing galanthamine obtained from a plant of the
Amaryllidaceae family, said mixture being dissolved in a solvent selected from
methanol, ethanol, propanol or isopropanol; b) recovery of the precipitate; c)
dissolution of the precipitate in a basic aqueous solution; d) extraction with a
solvent of general formula (II)

in which R1 is hydrogen or methyl and R2 is selected from n-butyl, isobutyl, sec-
butyl and t-butyl; e) concentration of the organic phase; f) recovery of the
precipitated galanthamine (I) by known method.

Documents:

02188-kolnp-2007-abstract.pdf

02188-kolnp-2007-assignment.pdf

02188-kolnp-2007-claims 1.0.pdf

02188-kolnp-2007-claims 1.1.pdf

02188-kolnp-2007-correspondence others 1.1.pdf

02188-kolnp-2007-correspondence others.pdf

02188-kolnp-2007-description complete.pdf

02188-kolnp-2007-form 1.pdf

02188-kolnp-2007-form 3 1.1.pdf

02188-kolnp-2007-form 3.pdf

02188-kolnp-2007-form 5.pdf

02188-kolnp-2007-gpa.pdf

02188-kolnp-2007-international exm report.pdf

02188-kolnp-2007-international publication.pdf

02188-kolnp-2007-international search report.pdf

02188-kolnp-2007-pct request form.pdf

02188-kolnp-2007-priority document.pdf

2188-KOLNP-2007-(13-02-2012)-CORRESPONDENCE.pdf

2188-KOLNP-2007-(21-09-2011)-ABSTRACT.pdf

2188-KOLNP-2007-(21-09-2011)-AMANDED PAGES OF SPECIFICATION.pdf

2188-KOLNP-2007-(21-09-2011)-DESCRIPTION (COMPLETE).pdf

2188-KOLNP-2007-(21-09-2011)-EXAMINATION REPORT REPLY RECIEVED.pdf

2188-KOLNP-2007-(21-09-2011)-FORM 1.pdf

2188-KOLNP-2007-(21-09-2011)-FORM 2.pdf

2188-KOLNP-2007-(21-09-2011)-FORM 3.pdf

2188-KOLNP-2007-(21-09-2011)-OTHERS.pdf

2188-KOLNP-2007-(21-09-2011)-PETITION UNDER RULE 137.pdf

2188-KOLNP-2007-ASSIGNMENT.pdf

2188-KOLNP-2007-CORRESPONDENCE.pdf

2188-KOLNP-2007-EXAMINATION REPORT.pdf

2188-KOLNP-2007-FORM 18-1.1.pdf

2188-kolnp-2007-form 18.pdf

2188-KOLNP-2007-FORM 3.pdf

2188-KOLNP-2007-FORM 5.pdf

2188-KOLNP-2007-GRANTED-ABSTRACT.pdf

2188-KOLNP-2007-GRANTED-CLAIMS.pdf

2188-KOLNP-2007-GRANTED-DESCRIPTION (COMPLETE).pdf

2188-KOLNP-2007-GRANTED-FORM 1.pdf

2188-KOLNP-2007-GRANTED-FORM 2.pdf

2188-KOLNP-2007-GRANTED-SPECIFICATION.pdf

2188-KOLNP-2007-OTHERS.pdf

2188-KOLNP-2007-PA.pdf

2188-KOLNP-2007-REPLY TO EXAMINATION REPORT.pdf

2188-KOLNP-2007-TRANSLATED COPY OF PRIORITY DOCUMENT.pdf

abstract-02188-kolnp-2007.jpg


Patent Number 251956
Indian Patent Application Number 2188/KOLNP/2007
PG Journal Number 16/2012
Publication Date 20-Apr-2012
Grant Date 18-Apr-2012
Date of Filing 14-Jun-2007
Name of Patentee INDENA S.P.A.
Applicant Address VIALE ORTLES, 12, I-20139 MILANO
Inventors:
# Inventor's Name Inventor's Address
1 GABETTA BRUNO INDENA S.P.A. VIALE ORTLES, 12, I-20139 MILANO
2 MERCALLI ENRICO INDENA S.P.A. VIALE ORTLES, 12, I-20139 MILANO, ITALY
PCT International Classification Number A61K 31/55
PCT International Application Number PCT/EP2005/012521
PCT International Filing date 2005-11-23
PCT Conventions:
# PCT Application Number Date of Convention Priority Country
1 MI2004A002413 2004-12-17 Italy